Loading...
Header Logo
Keywords
Last Name
Institution

Sanjay Johan Mathew

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Psychiatry & Behavioral Sciences
DivisionPsychiatry & Behavioral Sciences
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Research 
    Collapse research activities and funding
    K23MH069656     (MATHEW, SANJAY J)Sep 1, 2004 - Aug 31, 2010
    NIH/NIMH
    PROTON MRS STUDIES IN GENERALIZED ANXIETY DISORDER
    Role: Principal Investigator

    R01MH081870     (MATHEW, SANJAY J)Jul 23, 2009 - Apr 30, 2014
    NIH/NIMH
    Optimization of IV Ketamine for Treatment Resistant Major Depression
    Role: Principal Investigator

    R01MH085054     (MATHEW, SANJAY J)Aug 1, 2010 - Apr 30, 2014
    NIH/NIMH
    2/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression
    Role: Principal Investigator

    I01CX001205     (MATHEW, SANJAY J)Oct 1, 2015 - Sep 30, 2020
    VA
    Ketamine for Treatment Resistant Late-Life Depression
    Role: Principal Investigator

    R61MH110540     (MATHEW, SANJAY J)Sep 21, 2016 - Jul 31, 2019
    NIH/NIMH
    NMDA receptor modulation for hyperarousal in PTSD
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Schanzer B, Rivas-Grajales AM, Khan A, Mathew SJ. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov; 28(11):1003-1012. PMID: 31607187.
      View in: PubMed
    2. O'Brien B, Lijffijt M, Wells A, Swann AC, Mathew SJ. The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression. Pharmaceuticals (Basel). 2019 Sep 11; 12(3). PMID: 31514448.
      View in: PubMed
    3. Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 Jan 01; 260:131-139. PMID: 31494365.
      View in: PubMed
    4. Sakurai H, Dording C, Yeung A, Foster S, Jain F, Chang T, Trinh NH, Bernard R, Boyden S, Iqbal SZ, Wilkinson ST, Mathew SJ, Mischoulon D, Fava M, Cusin C. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord. 2019 Nov 01; 258:102-108. PMID: 31400624.
      View in: PubMed
    5. Dakwar E, Nunes EV, Hart CL, Foltin RW, Mathew SJ, Carpenter KM, Choi CJJ, Basaraba CN, Pavlicova M, Levin FR. A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Am J Psychiatry. 2019 Nov 01; 176(11):923-930. PMID: 31230464.
      View in: PubMed
    6. Mathew SJ, Rivas-Grajales AM. "Does the opioid system block or enhance the antidepressant effects of ketamine?" Chronic Stress (Thousand Oaks). 2019 Jan-Dec/; 3. PMID: 31276079.
      View in: PubMed
    7. Gould F, Dunlop BW, Rosenthal JB, Iosifescu DV, Mathew SJ, Neylan TC, Rothbaum BO, Nemeroff CB, Harvey PD. Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. Arch Clin Neuropsychol. 2019 Jun 01; 34(4):539-547. PMID: 30124744.
      View in: PubMed
    8. Hartwig EM, Rufino KA, Palmer CA, Shepard C, Alfano CA, Schanzer B, Mathew SJ, Patriquin MA. Trajectories of self-reported sleep disturbance across inpatient psychiatric treatment predict clinical outcome in comorbid major depressive disorder and generalized anxiety disorder. J Affect Disord. 2019 05 15; 251:248-255. PMID: 30953891.
      View in: PubMed
    9. Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Grunebaum M, Oquendo MA, Kadriu B, Akula N, Henter I, Yuan P, Merikangas K, Drevets W, Furey M, Mann JJ, McMahon FJ, Zarate CA, Shugart YY. Correction: Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl Psychiatry. 2019 03 05; 9(1):108. PMID: 30837454.
      View in: PubMed
    10. Jovanovic T, Duncan EJ, Kaye J, Garza K, Norrholm SD, Inslicht SS, Neylan TC, Mathew SJ, Iosifescu D, Rothbaum BO, Mayberg HS, Dunlop BW. Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. Psychophysiology. 2019 Feb 26; e13356. PMID: 30807663.
      View in: PubMed
    11. Lijffijt M, O'Brien B, Salas R, Mathew SJ, Swann AC. Interactions of immediate and long-term action regulation in the course and complications of bipolar disorder. Philos Trans R Soc Lond B Biol Sci. 2019 02 18; 374(1766):20180132. PMID: 30966917.
      View in: PubMed
    12. Wilkinson ST, Farmer C, Ballard ED, Mathew SJ, Grunebaum MF, Murrough JW, Sos P, Wang G, Gueorguieva R, Zarate CA. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology. 2019 06; 44(7):1233-1238. PMID: 30653192.
      View in: PubMed
    13. Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171. PMID: 30641350.
      View in: PubMed
    14. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2019 Jan 07. PMID: 30617276.
      View in: PubMed
    15. Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243. PMID: 30597688.
      View in: PubMed
    16. Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, Calabrese J, Goddard A, Goodman W, Lisanby SH, Smoski M, Weiner R, Iosifescu D, Nurnberger J, Szabo S, Murrough J, Shekhar A, Potter W. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nat Rev Drug Discov. 2018 12 28; 18(1):82-84. PMID: 30591715.
      View in: PubMed
    17. Mathew SJ, Wilkinson ST, Altinay M, Asghar-Ali A, Chang LC, Collins KA, Dale RM, Hu B, Krishnan K, Kellner CH, Malone DA, Murrough JW, Ostroff RB, Sanacora G, Shao M, Anand A. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemp Clin Trials. 2019 Feb; 77:19-26. PMID: 30572160.
      View in: PubMed
    18. Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Grunebaum M, Oquendo MA, Kadriu B, Akula N, Henter I, Yuan P, Merikangas K, Drevets W, Furey M, Mann JJ, McMahon FJ, Zarate CA, Shugart YY. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl Psychiatry. 2018 12 14; 8(1):280. PMID: 30552317.
      View in: PubMed
    19. Pape JC, Carrillo-Roa T, Rothbaum BO, Nemeroff CB, Czamara D, Zannas AS, Iosifescu D, Mathew SJ, Neylan TC, Mayberg HS, Dunlop BW, Binder EB. DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. Clin Epigenetics. 2018 11 03; 10(1):136. PMID: 30390684.
      View in: PubMed
    20. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2018 Oct 03. PMID: 30283029.
      View in: PubMed
    21. Wilkinson ST, Kiselycznyk C, Banasr M, Webler RD, Haile C, Mathew SJ. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord. 2018 12 01; 241:514-518. PMID: 30153634.
      View in: PubMed
    22. PeciƱa M, Karp JF, Mathew S, Todtenkopf MS, Ehrich EW, Zubieta JK. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry. 2019 04; 24(4):576-587. PMID: 29955162.
      View in: PubMed
    23. Hodgins GE, Blommel JG, Dunlop BW, Iosifescu D, Mathew SJ, Neylan TC, Mayberg HS, Harvey PD. Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder. J Clin Psychopharmacol. 2018 Jun; 38(3):200-206. PMID: 29505471.
      View in: PubMed
    24. Coplan JD, Lu D, El Sehamy AM, Tang C, Jackowski AP, Abdallah CG, Nemeroff CB, Owens MJ, Mathew SJ, Gorman JM. Early Life Stress Associated With Increased Striatal N-Acetyl-Aspartate: Cerebrospinal Fluid Corticotropin-Releasing Factor Concentrations, Hippocampal Volume, Body Mass and Behavioral Correlates. Chronic Stress (Thousand Oaks). 2018 Jan-Dec; 2. PMID: 29963652.
      View in: PubMed
    25. Coplan JD, Webler R, Gopinath S, Abdallah CG, Mathew SJ. Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ. J Affect Disord. 2018 03 15; 229:1-13. PMID: 29288871.
      View in: PubMed
    26. Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018 02 01; 175(2):150-158. PMID: 28969441.
      View in: PubMed
    27. Abdallah CG, Averill CL, Salas R, Averill LA, Baldwin PR, Krystal JH, Mathew SJ, Mathalon DH. Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Oct; 2(7):566-574. PMID: 29034354.
      View in: PubMed
    28. Dunlop BW, Binder EB, Iosifescu D, Mathew SJ, Neylan TC, Pape JC, Carrillo-Roa T, Green C, Kinkead B, Grigoriadis D, Rothbaum BO, Nemeroff CB, Mayberg HS. Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. Biol Psychiatry. 2017 Dec 15; 82(12):866-874. PMID: 28793974.
      View in: PubMed
    29. Patriquin MA, Mathew SJ. The Neurobiological Mechanisms of Generalized Anxiety Disorder and Chronic Stress. Chronic Stress (Thousand Oaks). 2017 Jan-Dec; 1. PMID: 29503978.
      View in: PubMed
    30. Mathew SJ, Gueorguieva R, Brandt C, Fava M, Sanacora G. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology. 2017 Dec; 42(13):2567-2574. PMID: 28553836.
      View in: PubMed
    31. Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017 Apr 01; 74(4):399-405. PMID: 28249076.
      View in: PubMed
    32. Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017 Jul; 16(7):472-486. PMID: 28303025.
      View in: PubMed
    33. Abdallah CG, Jackowski A, Salas R, Gupta S, Sato JR, Mao X, Coplan JD, Shungu DC, Mathew SJ. The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder. Neuropsychopharmacology. 2017 Jul; 42(8):1739-1746. PMID: 28272497.
      View in: PubMed
    34. Mathew SJ, Lijffijt M. Neurometabolic Abnormalities in Treatment-Resistant Depression. Am J Psychiatry. 2017 01 01; 174(1):3-5. PMID: 28041002.
      View in: PubMed
    35. Sanacora G, Johnson MR, Khan A, Atkinson SD, Riesenberg RR, Schronen JP, Burke MA, Zajecka JM, Barra L, Su HL, Posener JA, Bui KH, Quirk MC, Piser TM, Mathew SJ, Pathak S. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 42(4):844-853. PMID: 27681442.
      View in: PubMed
    36. Lijffijt M, Lane SD, Mathew SJ, Stanford MS, Swann AC. Heightened early-attentional stimulus orienting and impulsive action in men with antisocial personality disorder. Eur Arch Psychiatry Clin Neurosci. 2017 Oct; 267(7):697-707. PMID: 27662886.
      View in: PubMed
    37. Sharp C, Fowler JC, Salas R, Nielsen D, Allen J, Oldham J, Kosten T, Mathew S, Madan A, Frueh BC, Fonagy P. Operationalizing NIMH Research Domain Criteria (RDoC) in naturalistic clinical settings. Bull Menninger Clin. 2016; 80(3):187-212. PMID: 27583809.
      View in: PubMed
    38. Coplan JD, Kolavennu V, Abdallah CG, Mathew SJ, Perera TD, Pantol G, Carpenter D, Tang C. Patterns of anterior versus posterior white matter fractional anistotropy concordance in adult nonhuman primates: Effects of early life stress. J Affect Disord. 2016 Mar 01; 192:167-75. PMID: 26735328.
      View in: PubMed
    39. Raparia E, Coplan JD, Abdallah CG, Hof PR, Mao X, Mathew SJ, Shungu DC. Impact of childhood emotional abuse on neocortical neurometabolites and complex emotional processing in patients with generalized anxiety disorder. J Affect Disord. 2016 Jan 15; 190:414-423. PMID: 26551399.
      View in: PubMed
    40. Al Jurdi RK, Swann A, Mathew SJ. Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches. Curr Psychiatry Rep. 2015 Oct; 17(10):81. PMID: 26307033.
      View in: PubMed
    41. Bhagwagar Z, Torbeyns A, Hennicken D, Zheng M, Dunlop BW, Mathew SJ, Khan A, Weisler R, Nelson C, Shelton R, Thase ME, Lane R. Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies. J Clin Psychopharmacol. 2015 Aug; 35(4):454-9. PMID: 25961781.
      View in: PubMed
    42. Abdallah CG, Jackowski A, Sato JR, Mao X, Kang G, Cheema R, Coplan JD, Mathew SJ, Shungu DC. Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur Neuropsychopharmacol. 2015 Aug; 25(8):1082-90. PMID: 25983019.
      View in: PubMed
    43. Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, Foulkes A, Charney DS, Mathew SJ, Iosifescu DV. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015 Mar 13; 40(5):1084-90. PMID: 25374095.
      View in: PubMed
    44. Price RB, Mathew SJ. Does ketamine have anti-suicidal properties? Current status and future directions. CNS Drugs. 2015 Mar; 29(3):181-8. PMID: 25715884.
      View in: PubMed
    45. Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, Foulkes A, Mathew SJ, Charney DS, Murrough JW. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015 Mar; 76(3):247-52. PMID: 25271445.
      View in: PubMed
    46. DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015 May; 1345:47-58. PMID: 25649308.
      View in: PubMed
    47. Coplan J, Singh D, Gopinath S, Mathew SJ, Bulbena A. A Novel Anxiety and Affective Spectrum Disorder of Mind and Body-The ALPIM (Anxiety-Laxity-Pain-Immune-Mood) Syndrome: A Preliminary Report. J Neuropsychiatry Clin Neurosci. 2015; 27(2):93-103. PMID: 25923849.
      View in: PubMed
    48. Ridgewell C, Bray A, Curtis K, Velasquez K, Baldwin PR, Fowler JC, Mathew SJ, Salas R. Enhanced Olfactory Cortex Connectivity in a Patient With PTSD With Olfactory Hallucinations. J Neuropsychiatry Clin Neurosci. 2015; 27(2):e170-1. PMID: 25923873.
      View in: PubMed
    49. Coplan JD, Fulton SL, Reiner W, Jackowski A, Panthangi V, Perera TD, Gorman JM, Huang YY, Tang CY, Hof PR, Kaffman A, Dwork AJ, Mathew SJ, Kaufman J, Mann JJ. Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid in macaques following early life stress and inverse association with hippocampal volume: preliminary implications for serotonin-related function in mood and anxiety disorders. Front Behav Neurosci. 2014; 8:440. PMID: 25566007.
      View in: PubMed
    50. Coplan JD, Fathy HM, Jackowski AP, Tang CY, Perera TD, Mathew SJ, Martinez J, Abdallah CG, Dwork AJ, Pantol G, Carpenter D, Gorman JM, Nemeroff CB, Owens MJ, Kaffman A, Kaufman J. Early life stress and macaque amygdala hypertrophy: preliminary evidence for a role for the serotonin transporter gene. Front Behav Neurosci. 2014; 8:342. PMID: 25339875.
      View in: PubMed
    51. Abdallah CG, Salas R, Jackowski A, Baldwin P, Sato JR, Mathew SJ. Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol. 2015 May; 29(5):591-5. PMID: 25122038.
      View in: PubMed
    52. Dunlop BW, Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, Kinkead B, Kutner M, Iosifescu DV, Mathew SJ, Neylan TC, Kilts CD, Nemeroff CB, Mayberg HS. Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials. 2014 Jun 21; 15:240. PMID: 24950747.
      View in: PubMed
    53. Kaye JL, Dunlop BW, Iosifescu DV, Mathew SJ, Kelley ME, Harvey PD. Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports. J Psychiatr Res. 2014 Oct; 57:51-7. PMID: 24974001.
      View in: PubMed
    54. Lapidus KA, Gabbay V, Mao X, Johnson A, Murrough JW, Mathew SJ, Shungu DC. In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. Neurosci Lett. 2014 May 21; 569:74-9. PMID: 24704328.
      View in: PubMed
    55. Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, Soleimani L, Charney DS, Foulkes AL, Mathew SJ. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014 Apr; 31(4):335-43. PMID: 24668760.
      View in: PubMed
    56. Coplan JD, Fathy HM, Abdallah CG, Ragab SA, Kral JG, Mao X, Shungu DC, Mathew SJ. Reduced hippocampal N-acetyl-aspartate (NAA) as a biomarker for overweight. Neuroimage Clin. 2014; 4:326-35. PMID: 24501701.
      View in: PubMed
    57. Mathew SJ. Glycine transporter-I inhibitors: a new class of antidepressant? Biol Psychiatry. 2013 Nov 15; 74(10):710-1. PMID: 24144323.
      View in: PubMed
    58. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct; 170(10):1134-42. PMID: 23982301.
      View in: PubMed
    59. Murrough JW, Wan LB, Iacoviello B, Collins KA, Solon C, Glicksberg B, Perez AM, Mathew SJ, Charney DS, Iosifescu DV, Burdick KE. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology (Berl). 2013 Sep 11. PMID: 24022236.
      View in: PubMed
    60. Chang LC, Raty SR, Ortiz J, Bailard NS, Mathew SJ. The emerging use of ketamine for anesthesia and sedation in traumatic brain injuries. CNS Neurosci Ther. 2013 Jun; 19(6):390-5. PMID: 23480625.
      View in: PubMed
    61. Abdallah CG, Coplan JD, Jackowski A, Sato JR, Mao X, Shungu DC, Mathew SJ. Riluzole effect on occipital cortex: a structural and spectroscopy pilot study. Neurosci Lett. 2012 Nov 14; 530(1):103-7. PMID: 23043888.
      View in: PubMed
    62. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013 Aug 15; 74(4):250-6. PMID: 22840761.
      View in: PubMed
    63. Abdallah CG, Coplan JD, Jackowski A, Sato JR, Mao X, Shungu DC, Mathew SJ. A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. Eur Neuropsychopharmacol. 2013 Apr; 23(4):276-84. PMID: 22739126.
      View in: PubMed
    64. Aan Het Rot M, Zarate CA, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012 Oct 01; 72(7):537-47. PMID: 22705040.
      View in: PubMed
    65. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs. 2012 Mar 01; 26(3):189-204. PMID: 22303887.
      View in: PubMed
    66. Anand A, Gunn AD, Barkay G, Karne HS, Nurnberger JI, Mathew SJ, Ghosh S. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2012 Feb; 14(1):64-70. PMID: 22329473.
      View in: PubMed
    67. Coplan JD, Hodulik S, Mathew SJ, Mao X, Hof PR, Gorman JM, Shungu DC. The Relationship between Intelligence and Anxiety: An Association with Subcortical White Matter Metabolism. Front Evol Neurosci. 2011; 3:8. PMID: 22347183.
      View in: PubMed
    68. Shungu DC, Weiduschat N, Murrough JW, Mao X, Pillemer S, Dyke JP, Medow MS, Natelson BH, Stewart JM, Mathew SJ. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed. 2012 Sep; 25(9):1073-87. PMID: 22281935.
      View in: PubMed
    69. Coplan JD, Abdallah CG, Mathew SJ, Shungu DC, Mao X, Smith EL, Kaufman D, Gorman JM, Owens MJ, Nemeroff CB, Banerji MA, Rosenblum LA, Kral JG. Metabolic syndrome and neurometabolic asymmetry of hippocampus in adult bonnet monkeys. Physiol Behav. 2011 Jul 06; 103(5):535-9. PMID: 21459102.
      View in: PubMed
    70. Jackowski A, Perera TD, Abdallah CG, Garrido G, Tang CY, Martinez J, Mathew SJ, Gorman JM, Rosenblum LA, Smith EL, Dwork AJ, Shungu DC, Kaffman A, Gelernter J, Coplan JD, Kaufman J. Early-life stress, corpus callosum development, hippocampal volumetrics, and anxious behavior in male nonhuman primates. Psychiatry Res. 2011 Apr 30; 192(1):37-44. PMID: 21377844.
      View in: PubMed
    71. Feder A, Skipper J, Blair JR, Buchholz K, Mathew SJ, Schwarz M, Doucette JT, Alonso A, Collins KA, Neumeister A, Charney DS. Tryptophan depletion and emotional processing in healthy volunteers at high risk for depression. Biol Psychiatry. 2011 Apr 15; 69(8):804-7. PMID: 21377656.
      View in: PubMed
    72. Murrough JW, Perez AM, Mathew SJ, Charney DS. A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry. 2011 Mar; 72(3):414-5. PMID: 21450159.
      View in: PubMed
    73. Mathew SJ, Vythilingam M, Murrough JW, Zarate CA, Feder A, Luckenbaugh DA, Kinkead B, Parides MK, Trist DG, Bani MS, Bettica PU, Ratti EM, Charney DS. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol. 2011 Mar; 21(3):221-9. PMID: 21194898.
      View in: PubMed
    74. Coplan JD, Mathew SJ, Abdallah CG, Mao X, Kral JG, Smith EL, Rosenblum LA, Perera TD, Dwork AJ, Hof PR, Gorman JM, Shungu DC. Early-life stress and neurometabolites of the hippocampus. Brain Res. 2010 Oct 28; 1358:191-9. PMID: 20713023.
      View in: PubMed
    75. Krystal JH, Mathew SJ, D'Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs. 2010 Aug; 24(8):669-93. PMID: 20658799.
      View in: PubMed
    76. Murrough JW, Mao X, Collins KA, Kelly C, Andrade G, Nestadt P, Levine SM, Mathew SJ, Shungu DC. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. NMR Biomed. 2010 Jul; 23(6):643-50. PMID: 20661876.
      View in: PubMed
    77. Coplan JD, Abdallah CG, Tang CY, Mathew SJ, Martinez J, Hof PR, Smith EL, Dwork AJ, Perera TD, Pantol G, Carpenter D, Rosenblum LA, Shungu DC, Gelernter J, Kaffman A, Jackowski A, Kaufman J, Gorman JM. The role of early life stress in development of the anterior limb of the internal capsule in nonhuman primates. Neurosci Lett. 2010 Aug 16; 480(2):93-6. PMID: 20541590.
      View in: PubMed
    78. Abdallah CG, Tang CY, Mathew SJ, Martinez J, Hof PR, Perera TD, Shungu DC, Gorman JM, Coplan JD. Diffusion tensor imaging in studying white matter complexity: a gap junction hypothesis. Neurosci Lett. 2010 May 21; 475(3):161-4. PMID: 20371267.
      View in: PubMed
    79. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010 Jan 15; 67(2):139-45. PMID: 19897179.
      View in: PubMed
    80. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009 Sep 01; 66(5):522-6. PMID: 19545857.
      View in: PubMed
    81. Mathew SJ, Mao X, Keegan KA, Levine SM, Smith EL, Heier LA, Otcheretko V, Coplan JD, Shungu DC. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed. 2009 Apr; 22(3):251-8. PMID: 18942064.
      View in: PubMed
    82. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010 Feb; 13(1):71-82. PMID: 19288975.
      View in: PubMed
    83. aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009 Feb 03; 180(3):305-13. PMID: 19188629.
      View in: PubMed
    84. Mathew SJ, Charney DS. Publication bias and the efficacy of antidepressants. Am J Psychiatry. 2009 Feb; 166(2):140-5. PMID: 19188290.
      View in: PubMed
    85. Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, Murrough JW, Charney DS, Mathew SJ. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry. 2009 May 01; 65(9):792-800. PMID: 19058788.
      View in: PubMed
    86. Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donahue S. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. Clin Ther. 2008 Sep; 30(9):1658-66. PMID: 18840371.
      View in: PubMed
    87. Mathew SJ, Price RB, Charney DS. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet. 2008 May 15; 148C(2):89-98. PMID: 18412102.
      View in: PubMed
    88. Mathew S, Charney D. Anxiety and depression: leading edge of therapy. Mt Sinai J Med. 2008 May-Jun; 75(3):171-3. PMID: 18704975.
      View in: PubMed
    89. Hoffman EJ, Mathew SJ. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med. 2008 May-Jun; 75(3):248-62. PMID: 18704983.
      View in: PubMed
    90. Dumitriu D, Collins K, Alterman R, Mathew SJ. Neurostimulatory therapeutics in management of treatment-resistant depression with focus on deep brain stimulation. Mt Sinai J Med. 2008 May-Jun; 75(3):263-75. PMID: 18704979.
      View in: PubMed
    91. Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC, Donahue SR, Kauffman M, Iyer GR, Reinhard JF. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008 Apr; 28(2):235-9. PMID: 18344738.
      View in: PubMed
    92. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug; 33(9):2080-92. PMID: 18172433.
      View in: PubMed
    93. Mathew SJ. Treatment-resistant depression: recent developments and future directions. Depress Anxiety. 2008; 25(12):989-92. PMID: 19058261.
      View in: PubMed
    94. Mathew SJ, Price RB, Mao X, Smith EL, Coplan JD, Charney DS, Shungu DC. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry. 2008 May 01; 63(9):891-8. PMID: 18028881.
      View in: PubMed
    95. Amiel JM, Mathew SJ. Glutamate and anxiety disorders. Curr Psychiatry Rep. 2007 Aug; 9(4):278-83. PMID: 17880858.
      View in: PubMed
    96. Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med. 2006 Nov; 73(7):941-9. PMID: 17195879.
      View in: PubMed
    97. Coplan JD, Smith EL, Altemus M, Mathew SJ, Perera T, Kral JG, Gorman JM, Owens MJ, Nemeroff CB, Rosenblum LA. Maternal-infant response to variable foraging demand in nonhuman primates: effects of timing of stressor on cerebrospinal fluid corticotropin-releasing factor and circulating glucocorticoid concentrations. Ann N Y Acad Sci. 2006 Jul; 1071:525-33. PMID: 16891612.
      View in: PubMed
    98. Coplan JD, Mathew SJ, Mao X, Smith EL, Hof PR, Coplan PM, Rosenblum LA, Gorman JM, Shungu DC. Decreased choline and creatine concentrations in centrum semiovale in patients with generalized anxiety disorder: relationship to IQ and early trauma. Psychiatry Res. 2006 Jun 30; 147(1):27-39. PMID: 16797939.
      View in: PubMed
    99. Mathew SJ, Ho S. Etiology and neurobiology of social anxiety disorder. J Clin Psychiatry. 2006; 67 Suppl 12:9-13. PMID: 17092190.
      View in: PubMed
    100. Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry. 2005 Dec; 162(12):2379-81. PMID: 16330605.
      View in: PubMed
    101. Mathew SJ, Keegan K, Smith L. Glutamate modulators as novel interventions for mood disorders. Braz J Psychiatry. 2005 Sep; 27(3):243-8. PMID: 16224615.
      View in: PubMed
    102. Coplan JD, Altemus M, Mathew SJ, Smith EL, Sharf B, Coplan PM, Kral JG, Gorman JM, Owens MJ, Nemeroff CB, Rosenblum LA. Synchronized maternal-infant elevations of primate CSF CRF concentrations in response to variable foraging demand. CNS Spectr. 2005 Jul; 10(7):530-6. PMID: 16155510.
      View in: PubMed
    103. Feder A, Coplan JD, Goetz RR, Mathew SJ, Pine DS, Dahl RE, Ryan ND, Greenwald S, Weissman MM. Twenty-four-hour cortisol secretion patterns in prepubertal children with anxiety or depressive disorders. Biol Psychiatry. 2004 Aug 01; 56(3):198-204. PMID: 15271589.
      View in: PubMed
    104. Mathew SJ, Mao X, Coplan JD, Smith EL, Sackeim HA, Gorman JM, Shungu DC. Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. Am J Psychiatry. 2004 Jun; 161(6):1119-21. PMID: 15169704.
      View in: PubMed
    105. Mathew SJ, Shungu DC, Mao X, Smith EL, Perera GM, Kegeles LS, Perera T, Lisanby SH, Rosenblum LA, Gorman JM, Coplan JD. A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors. Biol Psychiatry. 2003 Oct 01; 54(7):727-35. PMID: 14512213.
      View in: PubMed
    106. Mathew SJ, Coplan JD, Goetz RR, Feder A, Greenwald S, Dahl RE, Ryan ND, Mann JJ, Weissman MM. Differentiating depressed adolescent 24 h cortisol secretion in light of their adult clinical outcome. Neuropsychopharmacology. 2003 Jul; 28(7):1336-43. PMID: 12784120.
      View in: PubMed
    107. Kent JM, Mathew SJ, Gorman JM. Molecular targets in the treatment of anxiety. Biol Psychiatry. 2002 Nov 15; 52(10):1008-30. PMID: 12437941.
      View in: PubMed
    108. Mathew SJ, Coplan JD, Smith EL, Scharf BA, Owens MJ, Nemeroff CB, Mann JJ, Gorman JM, Rosenblum LA. Cerebrospinal fluid concentrations of biogenic amines and corticotropin-releasing factor in adolescent non-human primates as a function of the timing of adverse early rearing. Stress. 2002 Sep; 5(3):185-93. PMID: 12186681.
      View in: PubMed
    109. Gorman JM, Mathew S, Coplan J. Neurobiology of early life stress: nonhuman primate models. Semin Clin Neuropsychiatry. 2002 Apr; 7(2):96-103. PMID: 11953933.
      View in: PubMed
    Mathew's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description